Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (11-20 of 190) with videos related to

Pageof 19
Sort By:
Open Access Rheumatology : Research and Reviews|July 13, 2009
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of lifeRoy Fleischmann
Expert Opinion on Drug Safety|August 9, 2003
Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritisRoy Fleischmann
Nature Clinical Practice. Rheumatology|July 1, 2008
Clinical studies can be performed in an ethical mannerRoy Fleischmann
Expert Review of Clinical Immunology|May 19, 2010
Anakinra in the treatment of rheumatic diseaseRoy Fleischmann
Expert Review of Clinical Immunology|February 7, 2022
Recent issues in JAK inhibitor safety: perspective for the clinicianRoy Fleischmann
Rheumatology and Therapy|January 7, 2019
A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019Roy Fleischmann
The Journal of Rheumatology|May 3, 2019
Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?Roy Fleischmann
Lancet (London, England)|February 21, 2017
Interleukin-6 inhibition for rheumatoid arthritisRoy Fleischmann
Clinical Rheumatology|September 25, 2021
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritisRoy Fleischmann
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2018
Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and BlackRoy Fleischmann
Pageof 19

Showing results (11-20 of 190) with videos related to

Sort By:
Pageof 19
Open Access Rheumatology : Research and Reviews|July 13, 2009
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of lifeRoy Fleischmann
Expert Opinion on Drug Safety|August 9, 2003
Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritisRoy Fleischmann
Nature Clinical Practice. Rheumatology|July 1, 2008
Clinical studies can be performed in an ethical mannerRoy Fleischmann
Expert Review of Clinical Immunology|May 19, 2010
Anakinra in the treatment of rheumatic diseaseRoy Fleischmann
Expert Review of Clinical Immunology|February 7, 2022
Recent issues in JAK inhibitor safety: perspective for the clinicianRoy Fleischmann
Rheumatology and Therapy|January 7, 2019
A Summary of 2018 and What Lies Ahead for Rheumatology and Therapy in 2019Roy Fleischmann
The Journal of Rheumatology|May 3, 2019
Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?Roy Fleischmann
Lancet (London, England)|February 21, 2017
Interleukin-6 inhibition for rheumatoid arthritisRoy Fleischmann
Clinical Rheumatology|September 25, 2021
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritisRoy Fleischmann
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2018
Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and BlackRoy Fleischmann
Pageof 19